Invivyd, Inc.

Equities

IVVD

US00534A1025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4 USD +9.29% Intraday chart for Invivyd, Inc. +25.79% +1.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stocks Edge -2- DJ
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Invivyd Clears Significant Hurdle After Pemgarda Authorization, Morgan Stanley Says MT
Top Premarket Gainers MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization MT
North American Morning Briefing : Tech in Focus on Reports of China Restrictions DJ
Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval DJ
Transcript : Invivyd, Inc. - Special Call
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt MT
Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults DJ
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial CI
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19 CI
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating MT
Invivyd Submits Request for Emergency Use Authorization to U.S. FDA for VYD222 for the Pre-Exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents CI
Invivyd Files Emergency Use Authorization Application for Antibody Candidate Against COVID-19 MT
North American Morning Briefing : S&P 500 Futures -2- DJ
Morgan Stanley Upgrades Invivyd to Equal-Weight From Underweight, Raises Price Target to $4 From $1 MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Top Midday Gainers MT
Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 CI
Invivyd, Inc.(NasdaqGM:IVVD) dropped from NASDAQ Biotechnology Index CI
Transcript : Invivyd, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Invivyd, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 12:55 PM
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 CI
Chart Invivyd, Inc.
More charts
Invivyd, Inc. is a biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. It delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify antibodies with a barrier to viral escape. It has a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including VYD222, a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5. VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4 USD
Average target price
9.667 USD
Spread / Average Target
+141.67%
Consensus